guid rais due strength higher core better
health busi grew msd due high demand
newborn screen china
achiev key mileston ce mark expect earli
latest lead launch
genom slightli due tough comp
thesi updat lot nois stronger euro
impact om core pre post euroimmun incom gain
lower tax rate pension account punchlin result
slightli reason better expect depend whether
bull bear share current pick dx base
core comp notabl challeng result expect
acceler other cite pf organ
auger well rel valuat go forward although would point
share alreadi seen improv base underli
price-to-earnings multipl standpoint much chang print
thought busi gener confirm
grower w/ solid omx potenti improv rel
cheap continu monitor result euroimmun
appear encourag await better entri point share despit
view upsid number also look see st model
result given odd mix slow core improv omx given
factor balanc view risk reward reiter
rate ep move slightli higher better core tax
pt move lower conserv view market multipl
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
 revenu bn euroimmun mm
 rais core ex-euroimmun vs core pro-forma fx tw rais mm vs mm prior
 dx ex euroimmun da rais vs prior
 america msd europ msd asia mid hsd
tax lower vs
ep rais vs ep prior
 o/p better core better tax
mm
brought mm
season lighter consist make
integr track
 msd biopharma hsd food msd environment msd industri lsd
industri weak due time anyth notabl weak europ apac
 msd america
 pronounc weak chemic petrochem
 still believ industri grow msd
euroimmun signific impact fx exposur
 rev yuan euro split
 expens germani expens euro
 hw om euro expens exceed euro rev
 overal expos yuan/euro flow oper profit
million except per share data fy end decemb organ analyt solut organ organ gp less total analyt solut op less ep share inc net inc price-to-earnings prem disc april
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america hold
articl articl
time dissemin april et
analyst ross muken vijay kumar luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
